RNA Therapy in the News

The article traces RNA’s expansion past vaccines into exon editing, circular RNA and in vivo CAR-T. Among the examples: SRT founder John Cooke, medical director of the RNA Therapeutics Program at Houston Methodist Research Institute, is reprogramming T cells inside the body with mRNA-carrying lipid nanoparticles to attack the pathogenic B cells behind autoimmune disease. It could be an order of magnitude cheaper than current CAR-T.

SRT Board Member Jeff Coller argues that the regulatory framework must be redesigned to treat personalized mRNA-CRISPR gene editing as "molecular surgery," validated once rather than approved as a new drug each time. The approach would transform KJ Muldoon's rescue from a singular miracle into a repeatable model for thousands of children born with rare mutations. The Society for RNA Therapeutics is positioned to provide the professional governance infrastructure this vision requires: setting manufacturing standards, establishing clinical guidelines, and brokering the public-private-regulatory partnerships that could make accredited Molecular Surgery Centers a reality.